MAP3K8 and melanoma: Given that Johannessen et al. 24 identified TPL2 as a MAPK pathway agonist that activates MEK independent of RAF signaling and drives resistance to RAF inhibition in melanoma, we hypothesized that TPL2 might be upregulated in B16BR cells.